VCM
FDMT icon

Versant Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Versant Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.68K Buy
728
+113
+18% +$1.1K ﹤0.01% 2241
2026
Q1 		$5.73K Hold
615
– – ﹤0.01% 2342
2025
Q4 		$4.61K Hold
615
– – ﹤0.01% 2282
2025
Q3 		$5.34K Buy
+615
New +$3.68K ﹤0.01% 2180

Other funds holding FDMT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
FFO
Fortitude Family Office Scottsdale, Arizona $516M AUM 28.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Versant Capital Management's FDMT Position: Q2 2026 in Review

Versant Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 18% in Q2 2026, buying an estimated $1.1K and bringing the position to 728 shares worth $9.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

Versant Capital Management first reported a position in FDMT in Q3 2025 and has held it in 4 quarters since. 9 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Versant Capital Management held 728 shares of 4D Molecular Therapeutics worth $9.68K as of Q2 2026.
  • Versant Capital Management bought 113 4D Molecular Therapeutics shares in Q2 2026, an estimated $1.1K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2241 holding.
  • Versant Capital Management first reported a position in 4D Molecular Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 9 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.